. 2015 Aug 7;21(29):8811–8816. doi: 10.3748/wjg.v21.i29.8811

Table 1.

Randomized phase III trials in the second-line treatment of gastric cancer

Trials	Treatment	No. of patients	OS (mo)	HR for OS (95%CI)	Remarks
AIO[8]	Irinotecan	21	4.0	0.48 (0.25-0.92)	Closed early due to poor accrual
AIO[8]	BSC	19	2.4	P = 0.012	Closed early due to poor accrual
Korean[9]	Docetaxel or irinotecan	133	5.3	0.657 (0.485-0.891)	No OS difference between docetaxel (5.5 mo) and irinotecan (6.5 mo)
Korean[9]	BSC	69	3.8	P = 0.007
COUGAR-02[10]	Docetaxel	84	5.2	0.67 (0.49-0.92)	Global QOL similar between arms (P = 0.53)
COUGAR-02[10]	BSC	84	3.6	P = 0.01	Global QOL similar between arms (P = 0.53)
REGARD[11]	Ramucirumab	238	5.2	0.776 (0.603-0.998)
REGARD[11]	Placebo	117	3.8	P = 0.047
RAINBOW[12]	Ramucirumab + paclitaxel	330	9.6	0.807 (0.678-0.962)
RAINBOW[12]	Placebo + paclitaxel	335	7.4	P = 0.017
WJOG 4007[15]	Paclitaxel	108	9.5	1.14 (0.88-1.49)
WJOG 4007[15]	Irinotecan	111	8.4	P = 0.24

BSC: Best supportive care; QOL: Quality of life.